1
|
Iyer GR, Darpo B, Xue H, Lecot J, Zack J, Bebrevska L, Weis W, Jones I, Drollmann A. Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants. Clin Pharmacol Drug Dev 2024; 13:572-584. [PMID: 38284433 DOI: 10.1002/cpdd.1374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 12/19/2023] [Indexed: 01/30/2024]
Abstract
Icenticaftor (QBW251) is a potentiator of the cystic fibrosis transmembrane receptor. Based on its mechanism of action, icenticaftor is expected to provide benefits in patients with chronic obstructive pulmonary disease by restoring mucociliary clearance, which would eventually lead to a reduction of bacterial colonization and related inflammatory cascade. A placebo- and positive-controlled, 4-way crossover thorough QT study was conducted in 46 healthy participants with the objective to assess the effect of therapeutic (300 mg twice daily for 6 days) and supratherapeutic (750 mg twice daily for 6 days) oral doses of icenticaftor on electrocardiogram parameters, including concentration-corrected QT (QTc) analysis. Moxifloxacin (400 mg, oral) was used as a positive control. In the concentration-QTc analysis performed on pooled data from Day 1 and Day 6 (steady state), the estimated population slope was shallow and slightly negative: -0.0012 ms/ng/mL. The effect on the Fridericia corrected QT (QTcF) interval (∆ΔQTcF) was predicted to be -1.3 milliseconds at the icenticaftor 300-mg twice-daily peak concentration (geometric mean was 1094 ng/mL) and -5.5 milliseconds at the 750-mg twice-daily peak concentration (geometric mean Cmax was 4529 ng/mL) indicated a mild shortening effect of icenticaftor on QTcF interval length. The results of the by-time-point analysis indicated least squares placebo corrected mean ∆∆QTcF across time points ranged from -7.9 to 0.1 milliseconds at 1 and 24 hours after dosing both on Day 6 in the 750-mg dose group compared with -3.7 to 1.6 milliseconds at 1.5 and 24 hours after dosing on Day 1 in the 300-mg dose group. Assay sensitivity was demonstrated with moxifloxacin. The large accumulation of exposures, especially the 4.3-fold increase in peak plasma concentration observed at the icenticaftor 750-mg twice-daily dosage compared with Icenticaftor 300 mg twice daily (2.3-fold) on Day 6 provided a large concentration range (up to 9540 ng/mL) to evaluate the effect of icenticaftor on ΔΔQTcF. Based on the concentration-QTc analysis, an effect on ΔΔQTcF exceeding 10 milliseconds can be excluded within the full observed ranges of plasma concentrations on icenticaftor, up to approximately 9540 ng/mL. Icenticaftor at the studied doses demonstrated a mild shortening in QTcF, which is unlikely to be of clinical relevance in a therapeutic setting.
Collapse
Affiliation(s)
- Ganesh R Iyer
- Biomedical Research, Novartis Pharmaceuticals Corporation, Cambridge, MA, USA
| | | | | | - Jean Lecot
- Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Julia Zack
- Biomedical Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | | | - Wendy Weis
- Biomedical Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - Ieuan Jones
- Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | | |
Collapse
|
2
|
Marasanapalle VP, Masimirembwa C, Sivasubramanian R, Sayyed S, Weinzierl-Hinum A, Mehta D, Kapungu NN, Kanji C, Thelingwani R, Zack J. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers. J Clin Pharmacol 2024; 64:578-589. [PMID: 37803948 DOI: 10.1002/jcph.2366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Accepted: 10/04/2023] [Indexed: 10/08/2023]
Abstract
This study investigated the differences in the pharmacokinetics (PK) of dextromethorphan and desipramine in healthy African volunteers to understand the effect of allelic variants of the human cytochrome P450 2D6 (CYP2D6) enzyme, namely the diplotypes of CYP2D6*1/*2 (*1*1, *1*2, *2*2) and the genotypes of CYP2D6*17*17 and CYP2D6*29*29. Overall, 28 adults were included and split into 3 cohorts after genotype screening: CYP2D6*1/*2 (n = 12), CYP2D6*17*17 (n = 12), and CYP2D6*29*29 (n = 4). Each subject received a single oral dose of dextromethorphan 30 mg syrup on day 1 and desipramine 50 mg tablet on day 8. The PK parameters of area under the plasma concentration-time curve from time of dosing to time of last quantifiable concentration (AUClast), and extrapolated to infinity (AUCinf), and the maximum plasma concentration (Cmax) were determined. For both dextromethorphan and desipramine, AUCinf and Cmax were higher in subjects of the CYP2D6*29*29 and CYP2D6*17*17 cohorts, as compared with subjects in the CYP2D6*1/*2 diplotype cohort and with normal metabolizers from the literature. All PK parameters, including AUCinf, Cmax, and the elimination half-life, followed a similar trend: CYP2D6*17*17 > CYP2D6*29*29 > CYP2D6*1/*2. The plasma and urinary drug/metabolite exposure ratios of both drugs were higher in subjects of the CYP2D6*17*17 and CYP2D6*29*29 cohorts, when compared with subjects in the CYP2D6*1/*2 diplotype cohort. All adverse events were mild, except in 1 subject with CYP2D6*17*17 who had moderately severe headache with desipramine. These results indicate that subjects with CYP2D6*17*17 and CYP2D6*29*29 genotypes were 5-10 times slower metabolizers than those with CYP2D6*1/*2 diplotypes. These findings suggest that dose optimization may be required when administering CYP2D6 substrate drugs in African patients. Larger studies can further validate these findings.
Collapse
Affiliation(s)
| | - Collen Masimirembwa
- African Institute of Biomedical Science & Technology (AiBST), Harare, Zimbabwe
| | | | | | | | - Dheeraj Mehta
- Novartis Healthcare Private Limited, Hyderabad, India
| | | | - Comfort Kanji
- African Institute of Biomedical Science & Technology (AiBST), Harare, Zimbabwe
| | - Roslyn Thelingwani
- African Institute of Biomedical Science & Technology (AiBST), Harare, Zimbabwe
| | - Julia Zack
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
| |
Collapse
|
3
|
Sangana R, Xu Y, Shah B, Tian X, Zack J, Shakeri-Nejad K, Kalluri S, Jones I, Ligueros-Saylan M, Taylor AF, Jain DK, Scosyrev E, Uddin A, Laurent N, Paganoni P. Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers. Clin Pharmacol Drug Dev 2024. [PMID: 38389387 DOI: 10.1002/cpdd.1373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Accepted: 12/19/2023] [Indexed: 02/24/2024]
Abstract
Omalizumab is an anti-IgE monoclonal antibody currently approved for the treatment of asthma, nasal polyps/chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. Omalizumab is available as an injection in a prefilled syringe (PFS) with a needle safety device (NSD). New product configurations were developed to reduce the number of injections per dose administration, improve patient convenience and treatment compliance. The objective of this randomized open-label 12-week study was to demonstrate pharmacokinetic bioequivalence between (1) new PFS with autoinjector (PFS-AI), (2) new PFS-NSD configuration, and (3) current PFS-NSD configuration. Each new configuration was considered bioequivalent to the current configuration if the confidence intervals (CIs) for the geometric mean ratios (GMR) were contained in the 0.80-1.25 range for maximum concentration (Cmax ), area under the concentration-time curve until the last quantifiable measurement (AUClast ), and AUC extrapolated to infinity (AUCinf ). Safety was assessed throughout the study. In total, 193 healthy volunteers were randomized at 1:1:1 ratio to omalizumab 1×300 mg/2 mL via new PFS-AI (n = 66), omalizumab 1×300 mg/2 mL via new PFS-NSD (n = 64), or omalizumab 2×150 mg/1 mL via current PFS-NSD (n = 63). Comparing new PFS-AI versus current PFS-NSD, the GMRs were: Cmax , 1.085; AUClast , 1.093; AUCinf , 1.100. Comparing new PFS-NSD versus current PFS-NSD, the GMRs were: Cmax , 1.006; AUClast , 1.016; AUCinf , 1.027. The 95% CIs for all GMR parameters were contained within the 0.80-1.25 range. Safety findings were consistent with the known safety profile of omalizumab. Single-dose omalizumab administered as the new PFS-AI or new PFS-NSD was bioequivalent to the current PFS-NSD.
Collapse
Affiliation(s)
| | - Yan Xu
- Genentech Research and Early Development, South San Francisco, CA, USA
| | - Bharti Shah
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - Xianbin Tian
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - Julia Zack
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | | | | | | | | | | | | | - Emil Scosyrev
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - Alkaz Uddin
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | | | - Paola Paganoni
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| |
Collapse
|
4
|
Prince WT, Venishetty VK, Lecot J, Shakeri‐Nejad K, Gray C, Taylor A, Iyer GR, Zack J. Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: A randomized, placebo- and positive-controlled thorough QT study in healthy individuals. Clin Transl Sci 2023; 16:1758-1767. [PMID: 37688315 PMCID: PMC10582667 DOI: 10.1111/cts.13564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2023] [Revised: 04/09/2023] [Accepted: 05/01/2023] [Indexed: 09/10/2023] Open
Abstract
Triclabendazole is an effective and well-tolerated treatment for human fascioliasis. A placebo- and positive-controlled, four-sequence by four-period crossover study was conducted in 45 healthy participants to assess the effect of therapeutic (10 mg/kg twice daily [b.i.d.] for 1 day) and supratherapeutic (10 mg/kg b.i.d. for 3 days) oral doses of triclabendazole on corrected QT (QTc) interval prolongation. Moxifloxacin (400 mg, oral) was used as a positive control. The highest mean placebo-corrected change from baseline in QTcF (ΔΔQTcF) on day 4 with triclabendazole was 9.2 at therapeutic dose ms and 21.7 ms at supratherapeutic dose, at 4 h postdose. The upper limit of the two-sided 90% confidence interval exceeded 10 ms across all timepoints, except at predose timepoint on day 4 in the therapeutic group indicating that an effect of triclabendazole on cardiac repolarization could not be excluded. However, triclabendazole had no clinically significant effects on heart rate and cardiac conduction at the studied doses. In the moxifloxacin group, the mean ΔΔQTcF peak value was 13.7 ms at 3 h on day 4. The assay sensitivity was confirmed. Maximum plasma concentration of triclabendazole, sulfoxide metabolite, and sulfone metabolite occurred at ~3-, 4-, and 6-h postdose, respectively. No deaths, serious adverse events, study discontinuations due to treatment-emergent adverse events, or clinically relevant abnormalities in laboratory evaluations and vital sign values were observed. This study showed that triclabendazole had no clinically relevant effects on heart rate and cardiac conduction; however, an effect on cardiac repolarization (ΔΔQTcF >10 ms) could not be excluded.
Collapse
Affiliation(s)
- William T. Prince
- Novartis Institutes for Biomedical Research, Novartis Pharmaceuticals CorporationCambridgeMassachusettsUSA
| | - Vinay Kumar Venishetty
- Novartis Institutes for Biomedical ResearchNovartis Healthcare Private LimitedHyderabadIndia
| | - Jean Lecot
- Novartis Institutes for Biomedical Research, Novartis Pharma AGBaselSwitzerland
| | - Kasra Shakeri‐Nejad
- Novartis Institutes for Biomedical Research, Novartis Pharma AGBaselSwitzerland
| | - Cathy Gray
- Novartis Institutes for Biomedical ResearchNovartis Pharmaceuticals CorporationEast HanoverNew JerseyUSA
| | - Amanda Taylor
- Novartis Institutes for Biomedical ResearchNovartis Pharmaceuticals CorporationEast HanoverNew JerseyUSA
| | - Ganesh R. Iyer
- Novartis Institutes for Biomedical Research, Novartis Pharmaceuticals CorporationCambridgeMassachusettsUSA
| | - Julia Zack
- Novartis Institutes for Biomedical ResearchNovartis Pharmaceuticals CorporationEast HanoverNew JerseyUSA
| |
Collapse
|
5
|
Pache L, Kim J, Marsden M, Layng F, Limpert A, Heimann D, Thienphrapa W, Cosford N, Zack J, Chanda S. PP 5.4 – 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents. J Virus Erad 2022. [DOI: 10.1016/j.jve.2022.100243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
6
|
Hoch M, Zack J, Quinlan M, Huth F, Forte S, Dodd S, Aimone P, Hourcade-Potelleret F. Pharmacokinetics of Asciminib When Taken With Imatinib or With Food. Clin Pharmacol Drug Dev 2021; 11:207-219. [PMID: 34609077 DOI: 10.1002/cpdd.1019] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Accepted: 08/03/2021] [Indexed: 12/17/2022]
Abstract
Asciminib, a first-in-class, Specifically Targeting the Abelson kinase Myristoyl Pocket (STAMP) inhibitor with the potential to overcome resistance to adenosine triphosphate-competitive tyrosine kinase inhibitors, is being investigated in leukemia as monotherapy and in combination with tyrosine kinase inhibitors including imatinib. This phase 1 study in healthy volunteers assessed the pharmacokinetics of asciminib (40 mg single dose) under 2 conditions: when taken with imatinib (steady state; 400 mg once daily) and a low-fat meal (according to imatinib prescription information), or when taken as single-agent under different food conditions. Asciminib plus imatinib with a low-fat meal increased asciminib area under the plasma concentration-time curve from time 0 to infinity and maximum plasma concentration (geometric mean ratios [90% confidence interval], 2.08 [1.93-2.24] and 1.59 [1.45-1.75], respectively) compared with asciminib alone under the same food conditions. Asciminib plus food decreased asciminib area under the plasma concentration-time curve from time 0 to infinity compared with asciminib taken under fasted conditions (geometric mean ratios: low-fat meal, 0.7 [0.631-0.776]; high-fat meal, 0.377 [0.341-0.417]). Asciminib plus imatinib was well tolerated with no new safety signals. Overall, coadministration of asciminib with imatinib and a low-fat meal results in a moderate increase in asciminib exposure compared with asciminib alone under the same food condition. Food itself decreases asciminib exposure, indicating that single-agent asciminib should be administered in the fasted state to prevent potential suboptimal exposures.
Collapse
Affiliation(s)
- Matthias Hoch
- Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Julia Zack
- Novartis Pharmaceuticals, East Hanover, New Jersey, USA
| | | | - Felix Huth
- Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | | | - Stephanie Dodd
- Novartis Pharmaceuticals, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA
| | | | | |
Collapse
|
7
|
Hoch M, Sato M, Zack J, Quinlan M, Sengupta T, Allepuz A, Aimone P, Hourcade-Potelleret F. Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment. J Clin Pharmacol 2021; 61:1454-1465. [PMID: 34115385 DOI: 10.1002/jcph.1926] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/12/2021] [Accepted: 06/08/2021] [Indexed: 12/17/2022]
Abstract
Asciminib is an investigational, first-in-class, specifically targeting the ABL myristoyl pocket (STAMP) inhibitor of BCR-ABL1 with a new mechanism of action compared with approved ATP-competitive tyrosine kinase inhibitors. This report describes the findings from 2 phase 1 studies assessing the pharmacokinetic (PK) profile of a single dose of asciminib (40 mg) in individuals with impaired renal function (based on absolute glomerular filtration rate; NCT03605277) or impaired hepatic function (based on Child-Pugh classification; NCT02857868). Individuals with severe renal impairment exhibited 49%-56% higher exposure (area under the curve [AUC]), with similar maximum plasma concentration (Cmax ), than matched healthy controls. Based on these findings, as per the protocol, the PK of asciminib in individuals with mild or moderate renal impairment was not assessed. In individuals with mild and severe hepatic impairment, asciminib AUC was 21%-22% and 55%-66% higher, respectively, and Cmax was 26% and 29% higher, respectively, compared with individuals with normal hepatic function. Individuals with moderate hepatic impairment had similar asciminib AUC and Cmax than matched healthy controls. The increase in asciminib AUC and Cmax in the mild hepatic impairment cohort was mainly driven by 1 participant with particularly high exposure. Asciminib was generally well tolerated, and the safety data were consistent with its known safety profile. In summary, these findings indicate that renal or hepatic impairment has no clinically meaningful effect on the exposure or safety profile of asciminib, and support its use in patients with varying degrees of renal or hepatic dysfunction.
Collapse
Affiliation(s)
- Matthias Hoch
- Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Masahiko Sato
- Novartis Institutes for Biomedical Research, Novartis Pharma K.K, Tokyo, Japan
| | - Julia Zack
- Novartis Pharmaceuticals, East Hanover, New Jersey, USA
| | | | | | | | | | | |
Collapse
|
8
|
Wang X, Bartels C, Kulkarni S, Sangana R, Jain M, Zack J, Yu J. Population Pharmacokinetic Analysis of Fevipiprant in Healthy Subjects and Asthma Patients using a Tukey’s g-and-h Distribution. Drug Res (Stuttg) 2021; 71:326-334. [PMID: 33682912 DOI: 10.1055/a-1381-6579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Abstract
Aim The objective of this analysis was to characterize the population pharmacokinetics (PK) of fevipiprant in asthma patients and to evaluate the effect of baseline covariates on the PK of fevipiprant.
Methods PK data from 1281 healthy subjects or asthma patients were available after single or once daily dosing of fevipiprant. Population PK analysis was conducted to describe fevipiprant plasma concentration data using a non-linear mixed effect modeling approach.
Results Fevipiprant PK was described by a two-compartment model with first-order absorption and first-order elimination. Exploration of fevipiprant PK in the population from the phase III studies revealed an over-dispersed and skewed distribution. This unusual distribution was described using Tukey’s g-and-h distribution (TGH) on the between-subject variability of apparent clearance (CL/F). The model identified a significant impact of disease status on CL/F, with the value in healthy subjects being 62% higher than that in asthma patients. Bodyweight, age and renal function showed statistically significant impact on fevipiprant clearance; however, compared with a typical asthma patient, the simulated difference in steady-state exposure was at most 16%.
Conclusion Fevipiprant PK was described by a two-compartment model with first-order absorption and first-order elimination. The TGH distribution was appropriate to describe the over-dispersed and skewed PK data as observed in the current studies. Asthma patients had approximately 37% higher exposure than healthy subjects did. Other covariates changed exposure by at most 16%.
Collapse
Affiliation(s)
- Xinting Wang
- Biostatistics & Pharmacometrics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Christian Bartels
- Biostatistics & Pharmacometrics, Novartis Pharma AG, Basel, Switzerland
| | - Swarupa Kulkarni
- PK Science, Novartis Pharmaceutics Corporation, East Hanover, NJ, USA
| | | | - Monish Jain
- PK Science, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Julia Zack
- PK Science, Novartis Pharmaceutics Corporation, East Hanover, NJ, USA
| | - Jing Yu
- Biostatistics & Pharmacometrics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| |
Collapse
|
9
|
Kudrolli H, Murray A, Tirpak L, Matin A, Zack J. PO-1320: A machine QA tool to verify targeting accuracy of off-isocenter metastases. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01338-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Kim J, Carmona C, Farrell K, Zhang T, Chen H, Dimpasoc M, Soliman M, Marsden M, Sun R, Zack J. Effect of natural killer cells on viral rebound in HIV-1-infected humanized mice. J Virus Erad 2019. [DOI: 10.1016/s2055-6640(20)30117-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
11
|
Doyle E, Custodio J, Pang PS, Das M, Cao H, Ma G, Mathias A, Zack J. Lack of Drug Interactions Between Boosted and Unboosted Tenofovir Alafenamide-Based Antiretroviral Single Tablet Regimens (Emtricitabine/Rilpivirine/Tenofovir Alafenamide and Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the Anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir. Open Forum Infect Dis 2015. [DOI: 10.1093/ofid/ofv131.80] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Zack J, Berg J, Juan A, Pannacciulli N, Allard M, Gottwald M, Zhang H, Shao Y, Ben-Yehuda O, Jochelson P. Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus. Clin Pharmacol Drug Dev 2015; 4:121-9. [PMID: 27128216 DOI: 10.1002/cpdd.174] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2013] [Accepted: 11/04/2014] [Indexed: 01/05/2023]
Abstract
Ranolazine and metformin may be frequently co-administered in subjects with chronic angina and co-morbid type 2 diabetes mellitus (T2DM). The potential for a drug-drug interaction was explored in two phase 1 clinical studies in subjects with T2DM to evaluate the pharmacokinetics and safety of metformin 1000 mg BID when administered with ranolazine 1000 mg BID (Study 1, N = 28) or ranolazine 500 mg BID (Study 2, N = 25) as compared to metformin alone. Co-administration of ranolazine 1000 mg BID with metformin 1000 mg BID resulted in 1.53- and 1.79-fold increases in steady-state metformin Cmax and AUCtau , respectively; co-administration of ranolazine 500 mg BID with metformin 1000 mg BID resulted in 1.22- and 1.37-fold increases in steady-state metformin Cmax and AUCtau , respectively. Co-administration of ranolazine and metformin was well tolerated in these T2DM subjects, with no serious adverse events or drug-related adverse events leading to discontinuation. The most common adverse events were nausea, diarrhea, and dizziness. These findings are consistent with a dose-related interaction between ranolazine and metformin, and suggest that a dose adjustment of metformin may not be required with ranolazine 500 mg BID; whereas, the metformin dose should not exceed 1700 mg of total daily dose when using ranolazine 1000 mg BID.
Collapse
Affiliation(s)
- Julia Zack
- Gilead Sciences, Inc., Foster City, CA, USA
| | - Jolene Berg
- DaVita Clinical Research, Minneapolis, MN, USA
| | - Axel Juan
- SeaView Research, Inc., Miami, FL, USA
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Tornatore KM, Brazeau D, Dole K, Danison R, Wilding G, Leca N, Gundroo A, Gillis K, Zack J, DiFrancesco R, Venuto RC. Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients. J Clin Pharmacol 2013; 53:1039-47. [DOI: 10.1002/jcph.123] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2013] [Accepted: 05/25/2013] [Indexed: 12/19/2022]
Affiliation(s)
| | - Daniel Brazeau
- Pharmaceutical Genomics Laboratory; Department of Pharmaceutical Sciences; School of Pharmacy and Pharmaceutical Sciences, University at Buffalo; Buffalo; NY; USA
| | - Kiran Dole
- Department of Pharmacy Practice; Translational Pharmacology Research Core, Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo; Buffalo; NY; USA
| | - Ryan Danison
- Department of Biostatistics; School of Public Health and Health Professions, University at Buffalo; Buffalo; NY; USA
| | - Gregory Wilding
- Department of Biostatistics; School of Public Health and Health Professions, University at Buffalo; Buffalo; NY; USA
| | - Nicolae Leca
- Division of Nephrology, Department of Medicine; School of Medicine and Biomedical Sciences, Erie County Medical Center, University at Buffalo; Buffalo; NY; USA
| | - Aijaz Gundroo
- Division of Nephrology, Department of Medicine; School of Medicine and Biomedical Sciences, Erie County Medical Center, University at Buffalo; Buffalo; NY; USA
| | - Kathryn Gillis
- Department of Pharmacy Practice; Translational Pharmacology Research Core, Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo; Buffalo; NY; USA
| | - Julia Zack
- Department of Pharmacy Practice; Translational Pharmacology Research Core, Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo; Buffalo; NY; USA
| | - Robin DiFrancesco
- Department of Pharmacy Practice; Translational Pharmacology Research Core, Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo; Buffalo; NY; USA
| | - Rocco C. Venuto
- Division of Nephrology, Department of Medicine; School of Medicine and Biomedical Sciences, Erie County Medical Center, University at Buffalo; Buffalo; NY; USA
| |
Collapse
|
14
|
Tornatore KM, Sudchada P, Dole K, DiFrancesco R, Leca N, Gundroo AC, Danison RT, Attwood K, Wilding GE, Zack J, Forrest A, Venuto RC. Mycophenolic Acid Pharmacokinetics During Maintenance Immunosuppression in African American and Caucasian Renal Transplant Recipients. J Clin Pharmacol 2013; 51:1213-22. [DOI: 10.1177/0091270010382909] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Staehr PM, Dhalla AK, Zack J, Wang X, Ho YL, Bingham J, Belardinelli L. Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol 2013; 53:385-92. [PMID: 23427000 DOI: 10.1002/jcph.9] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2012] [Accepted: 06/24/2012] [Indexed: 11/09/2022]
Abstract
GS-9667, a new selective, partial agonist of the A(1) adenosine receptor (AR), may represent an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA). The objectives of the studies were to evaluate the effects of single and multiple doses of GS-9667 on plasma FFA concentrations, its pharmacokinetics (PK) and safety/tolerability. Two studies were conducted. In the single ascending dose study, healthy, non-obese, and obese subjects received a single oral dose of GS-9667 (30-1,800 mg). In the multiple, ascending dose study, healthy, obese subjects received GS-9667 (600-2,400 mg QD, 1,200 mg BID, or 600 mg QID) for 14 days. Blood and urine samples were collected for lipid profiling and PK analyses. The ECG, vital signs, and subject tolerability were monitored. Doses of GS-9667 ≥300 mg caused dose-dependent reductions in FFA levels that were reproducible over 14 days without evidence of desensitization or rebound. All doses were well tolerated. GS-9667 was rapidly absorbed and distributed; Steady-state concentrations were achieved within 3-5 days. The A(1) AR partial agonist GS-9667 reduced plasma FFA, exhibited linear kinetics, and was well-tolerated in healthy non-obese and obese subjects.
Collapse
|
16
|
Venitz J, Zack J, Gillies H, Allard M, Regnault J, Dufton C. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol 2011; 52:1784-805. [PMID: 22205719 DOI: 10.1177/0091270011423662] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The authors review the basic pharmacology and potential for adverse drug-drug interactions (DDIs) of bosentan and ambrisentan, the 2 endothelin receptor antagonists currently approved for pulmonary arterial hypertension (PAH) treatment. Bosentan, an endothelin (ET) receptor-type ET(A) and ET(B) antagonist, is metabolized to active metabolites by and an inducer of cytochrome P450 (CYP)2C9 and CYP3A. Ambrisentan, a selective ET(A) receptor antagonist, is metabolized primarily by uridine 5'diphosphate glucuronosyltransferases (UGTs) 1A9S, 2B7S, and 1A3S and, to a lesser extent, by CYP3A and CYP2C19. Drug interactions observed with bosentan DDI studies have demonstrated a potential for significant clinical implications during PAH management: bosentan is contraindicated with cyclosporine A and glyburide, and additional monitoring/dose adjustments are required when coadministered with hormonal contraceptives, simvastatin, lopinavir/ritonavir, and rifampicin. As bosentan carries a boxed warning regarding risks of liver injury and showed dose-dependant increases in serum aminotransferase abnormalities, drug interactions that increase bosentan exposure are of particular clinical concern. Ambrisentan DDI studies performed to date have shown only one clinically relevant DDI, an interaction with cyclosporine A that requires ambrisentan dose reduction. As the treatment of PAH moves toward multimodal combination therapy, scrutiny should be placed on ensuring that drug combinations achieve maximal clinical benefit while minimizing side effects.
Collapse
Affiliation(s)
- Jürgen Venitz
- Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Room 450B, R.B. Smith Building, 410 N 12th Street, PO Box 980533, Richmond, VA 23298-0533, USA.
| | | | | | | | | | | |
Collapse
|
17
|
Epeldegui M, Kitchen S, De La Cruz J, Zack J, Martinez-Maza O. HIV induces the expression of activation-induced cytidine deaminase (AICDA) in B cells through a direct interaction between virion-associated CD40L and CD40. Infect Agent Cancer 2009. [PMCID: PMC4261708 DOI: 10.1186/1750-9378-4-s2-o11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
18
|
Amado RG, Mitsuyasu RT, Symonds G, Rosenblatt JD, Zack J, Sun LQ, Miller M, Ely J, Gerlach W. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther 1999; 10:2255-70. [PMID: 10498256 DOI: 10.1089/10430349950017239] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- R G Amado
- Department of Medicine and UCLA AIDS Institute, Los Angeles, CA 90095-1678, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Bennett R, Goodman M, Hessinger J, Kahn H, Ligget J, Marshall G, Zack J. Using multimedia in large-scale computer-based testing programs. Computers in Human Behavior 1999. [DOI: 10.1016/s0747-5632(99)00024-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
20
|
Abstract
The Vif protein of human immunodeficiency virus type 1 (HIV-1) is important for virion infectivity. Previous studies have shown that vif mutant HIV-1 virions are defective in their ability to synthesize proviral DNA in vivo. Here, we examine the role of Vif in viral DNA synthesis in the endogenous reverse transcriptase (RT) reaction, an in vitro assay in which virions synthesize viral DNA by using endogenous viral RNA as a template. vif mutant virions showed a significant reduction in endogenous RT activity despite similar levels of exogenous RT activity. Analysis of the viral DNA products on agarose gels demonstrated that this reflects reduced synthesis of short minus- and plus-strand DNA products in addition to those of full genomic length. Quantitative PCR analysis of endogenous reverse transcription provided further evidence for reduced formation of both initial and completed reverse transcripts. Vif had no effect on genomic RNA dimerization or the stability of the RNA dimer linkage. These results suggest that Vif is important for an early event after virus entry but preceding or during the early stages of viral DNA synthesis. This may be due to an intrinsic effect on reverse transcription or a preceding postentry event(s), such as virion uncoating or disassembly of the virion core. Drugs targeted to Vif function may provide a new therapeutic approach to inhibiting HIV-1 reverse transcription.
Collapse
Affiliation(s)
- J Goncalves
- Division of Human Retrovirology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
| | | | | | | |
Collapse
|
21
|
Merrill JE, Koyanagi Y, Zack J, Thomas L, Martin F, Chen IS. Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1. J Virol 1992; 66:2217-25. [PMID: 1548758 PMCID: PMC289014 DOI: 10.1128/jvi.66.4.2217-2225.1992] [Citation(s) in RCA: 167] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Cytokines such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF alpha) are produced by leukocytes and play a role in immune responses. They also function in normal brain physiology as well as in pathological conditions within the central nervous system, where they are produced by brain macrophages (microglia) and brain astrocytes. In this study, we document the ability of human immunodeficiency virus type 1 (HIV-1) to induce TNF alpha and IL-1 in primary rat brain cultures. While productive infection did not occur in these cells, it was not required for cytokine induction. Using monocyte/macrophage-tropic (JRFL) and T-cell-tropic (IIIB) strains of HIV-1, we were able to induce cytokines in both microglia and astrocytes. In addition to whole virus, recombinant envelope proteins also induced these cytokines. The induction of IL-1 and TNF alpha could be blocked by a panel of antibodies recognizing epitopes in the gp120 and gp41 areas of the envelope. Soluble recombinant CD4 did not block TNF alpha and IL-1 production. If TNF alpha and IL-1 can be induced in brain tissue by HIV-1, they may contribute to some of the neurologic disorders associated with AIDS.
Collapse
Affiliation(s)
- J E Merrill
- Department of Neurology, Reed Neurological Research Center, UCLA School of Medicine 90024-1678
| | | | | | | | | | | |
Collapse
|
22
|
Cann AJ, Churcher MJ, Boyd M, O'Brien W, Zhao JQ, Zack J, Chen IS. The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol 1992; 66:305-9. [PMID: 1727490 PMCID: PMC238288 DOI: 10.1128/jvi.66.1.305-309.1992] [Citation(s) in RCA: 108] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Different isolates of human immunodeficiency virus type 1 (HIV-1) vary in the cell tropisms they display, i.e., the range of cell types in which they are able to establish a productive infection. Here, we report on the phenotypes of recombinants between two molecularly cloned strains of HIV-1. Our results prove that the envelope glycoprotein gp120 is solely responsible for the difference in cell tropism between the two parental isolates and that no other genes or sequences are involved in determining the cell tropism of these strains. The region of the envelope involved in the determination of cell tropism includes sequences which encode the V3 loop of gp120. Control of cell tropism by this region of the virus env gene is a general phenomenon which applies to many different HIV-1 isolates.
Collapse
Affiliation(s)
- A J Cann
- Department of Microbiology, University of Leicester, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
23
|
Yancu Y, Szeinberg A, Rosenman Y, Blau H, Zack J, Yahav J. [Pneumothorax in cystic fibrosis: intrapleural instillation of Atabrine]. Harefuah 1991; 120:264-6. [PMID: 1869120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Intrapleural instillation of quinacrine HC1 (Atabrine) was used to treat spontaneous pneumothorax in 2 young men, aged 26 and 36 years, respectively, with advanced pulmonary disease due to cystic fibrosis. Pneumothorax did not recur until 1 year later in 1 case and 2 years later in the other. This mode of therapy for pneumothorax provides a valuable alternative to surgery for the patient with cystic fibrosis, severe lung disease and marginal pulmonary reserve. Quinacrine sclerosis should be considered for management of pneumothorax in cystic fibrosis because of the high rate of recurrence. However, caution should be exercised since heart-lung transplantation cannot be performed after pleural sclerosis.
Collapse
Affiliation(s)
- Y Yancu
- Pediatric Pulmonary Clinic, Chaim Sheba Medical Center, Tel Hashomer
| | | | | | | | | | | |
Collapse
|
24
|
Zack J, Smith RG, Ozanne B. Characterization of a leukemia-derived transforming growth factor. Leukemia 1987; 1:737-45. [PMID: 3500371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
A novel transforming growth factor activity has been identified in the serum-free medium derived from cultures of SMS-SB cells, a human pre-B acute lymphoblastic leukemia cell line. This activity (leukemia-derived transforming growth factor) was biochemically distinct from known fibroblast mitogens such as epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, platelet-derived growth factor, and the endothelial cell growth factor/fibroblast growth factor family of mitogens. Leukemia-derived transforming growth factor was heterogeneous on heparin affinity chromatography, fractionating into three peaks of activity. Although these peaks differed in dose-response characteristics in agar colony and mitogenic assays, each activity was similarly inactivated by heat, acid treatment, and sulfhydryl reduction. Each of the heparin derivatives also behaved similarly on gel filtration and diethylaminoethyl chromatography. Leukemia-derived transforming growth factor was not mitogenic for normal or leukemic lymphocytes or granulocyte/macrophage progenitors. Therefore, a direct or autocrine function for this activity seems unlikely.
Collapse
Affiliation(s)
- J Zack
- Department of Microbiology, University of Texas Health Science Center, Dallas 75235
| | | | | |
Collapse
|
25
|
Ozanne B, Wheeler T, Zack J, Smith G, Dale B. Transforming gene of a human leukaemia cell is unrelated to the expressed tumour virus related gene of the cell. Nature 1982; 299:744-7. [PMID: 7121605 DOI: 10.1038/299744a0] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The virally encoded oncogenes (v-onc) of avian and mammalian retroviruses are the recombinant products of normal cellular genes (c-onc) and a retroviral genome. These cellular homologues have been highly conserved during evolution and are found in human DNA. The expression of at least one c-onc under the control of a viral promoter results in transformation of cells in a manner resembling that displayed by the v-onc counterpart; the inappropriate expression of c-onc in the absence of viral influences could likewise result in the malignant state. This proposal would be strongly supported by the presence of c-onc RNAs in a variety of human tumours were they not also demonstrable in normal tissues. The role of these RNAs in the oncogenic process remains unclear. Here we report that RNA homologous to the oncogene (v-abl) of Abelson murine leukaemia virus (A-MLV) is expressed in a unique human leukaemia in a fashion different from that of other human tissues and tumours. In addition, DNA from this tumour transforms NIH-3T3 cells at a high efficiency in a transfection assay. The transfected sequences are not related to the v-abl gene, but the NIH-3T3 transformants manufacture a transforming growth factor which behaves similarly to factors produced by A-MLV-transformed NIH-3T3 fibroblasts.
Collapse
|